NGNE241220P25000
- 1.65
- 0.000.00%
Neurogene Newsroom
Neurogene Adjusts Clinical Trial After Setback
Express News | Neurogene Shares Shares Down 5.5% After the Bell Following Announcement That Trial Participant Died, FDA Allowing It to Proceed With Trial for Rett Syndrome
Express News | Neurogene Inc - FDA Allows Neurogene to Proceed With Phase 1/2 Trial Using 1E15 Vg Dose
Express News | Neurogene Inc - Participant in Neurogene's Phase 1/2 Trial for Rett Syndrome Dies
Stifel Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $46
Express News | Neurogene Inc : Stifel Cuts Target Price to $46 From $60
Stifel Maintains Neurogene(NGNE.US) With Buy Rating, Raises Target Price to $46
TD Cowen Maintains Neurogene(NGNE.US) With Buy Rating
Neurogene's Resilient Clinical Progress and Strong Financial Position Support Buy Rating
Neurogene Is Maintained at Outperform by BMO Capital
Neurogene Inc. Faces Uncertainty With NGN-101 Program Amid FDA Challenges and Strategic Hurdles
BMO Capital Maintains Neurogene(NGNE.US) With Buy Rating, Cuts Target Price to $60
A Quick Look at Today's Ratings for Neurogene(NGNE.US), With a Forecast Between $46 to $60
Promising Outlook for Neurogene's Low-Dose NGN-401 Program in Rett Syndrome
Neurogene Analyst Ratings
Neurogene Price Target Lowered to $46 From $72 at Baird
Mitchell Kapoor Recommends Buy for Neurogene Due to Strong NGN-401 Low-Dose Safety and Potential Upside
Neurogene Selloff on Safety Event an Overreaction, Says H.C. Wainwright
Neoleukin Therapeutics GAAP EPS of -$1.19 In-line
Neurogene: Q3 Earnings Snapshot